<DOC>
	<DOCNO>NCT01300208</DOCNO>
	<brief_summary>This first study cutaneous lupus erythematosus subject evaluate safety , tolerability , pharmacokinetics , pharmacodynamics , efficacy CC-11050 .</brief_summary>
	<brief_title>To Evaluate Preliminary Safety , Tolerability , Pharmacokinetics , Pharmacodynamics Efficacy CC-11050 Subjects With Discoid Lupus Erythematosus Subacute Cutaneous Lupus Erythematosus</brief_title>
	<detailed_description />
	<mesh_term>Lupus Erythematosus , Systemic</mesh_term>
	<mesh_term>Lupus Erythematosus , Cutaneous</mesh_term>
	<mesh_term>Lupus Erythematosus , Discoid</mesh_term>
	<criteria>Key Subjects clinical diagnosis discoid lupus erythematosus sub acute lupus erythematosus &gt; 16 week prior screen consistent histological finding skin biopsy base Gilliam classification candidate systemic therapy ( determined Investigator ) Must , opinion Investigator , active skin lesion sufficient severity Screening Baseline ( Cutaneous Lupus Area Severity Index Activity Score ≥ 10 ) All subject take hydroxychloroquine , chloroquine quinacrine study must documentation ophthalmologic exam perform within 24 week Baseline Visit . Must meet follow laboratory criterion : White blood cell count ≥3000/mm3 ( ≥ 3.0 x 109/L ) &lt; 14,000/mm3 ( &lt; 14 x 109/L ) Absolute neutrophil count ( ANC ) &gt; 1500 cells/μL ( 1.5 x 109/L ) Platelet count ≥ 100,000/μL ( ≥ 100 x 109/L ) Serum creatinine ≤ 1.5 mg/dL ( ≤ 132.6 μmol/L ) Aspartate aminotransferase ( AST/SGOT ) alanine aminotransferase ( ALT/SGPT ) ≤ 1.5 X upper limit normal ( ULN ) Total bilirubin &lt; 2mg/dL Hemoglobin &gt; 11 g/dL Key Exclusion Criteria Participation multiple CC11050 cohorts previous exposure CC11050 Presence history SLE base investigator ' clinical evaluation subject exhibit medically significant ( determined Investigator ) LErelated pleuritis , pericarditis , neurologic , renal and/or major SLErelated organ system involvement ( SLErelated SLE joint involvement acceptable ) . Use topical local therapy know possibly benefit discoid lupus erythematosus SCLE sub acute lupus erythematosus within 2 week Screening Visit Use concomitant disease modify antirheumatic drug ( DMARDs ) exception antimalarial within 4 week screen Use topical local therapy know possibly benefit discoid lupus erythematosus SCLE sub acute lupus erythematosus within 2 week Screening Visit Use immunosuppressive ( eg , azathioprine , mycophenolate mofetil , methotrexate , etc . ) within 4 week screen</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>cutaneous lupus erythematosus</keyword>
	<keyword>subacute lupus erythematosus</keyword>
	<keyword>discoid lupus erythematosus</keyword>
	<keyword>lupus</keyword>
</DOC>